CUDR as biomarker for cancer progression and therapeutic response

• US 20080044828A1
• Filed: 12/08/2006
• Published: 02/21/2008
• Est. Priority Date: 02/04/2004
• Status: Active Grant

• Current Assignee: Tim Kwok
• Original Assignee: Tim Kwok
• Inventors: Kwok, Tim
• Granted Patent: US 7,557,204 B2
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07H 21/04 with deoxyribosyl as saccharide radical
• CPC Class Codes: C07K 14/82 Translation products from oncogenes
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 33/57488 involving compounds identifable in body fluids
• CPC Class Codes: Y10T 436/143333 Saccharide [e.g., DNA, etc.]

Abstract

Disclosed is a novel human gene designated CUDR. Provides is also a CUDR gene as a biomarker in the diagnosis of human cancers and a cancer therapy.

Claims

1-6. -6. (canceled)

7. A kit for diagnosing a tumor or evaluating the treatment outcome of an anticancer agent in a subject, with the proviso that the tumor is not an estrogen receptor alpha positive breast cancer, comprising:

a pair of primers for amplification or a probe for hybridization of cDNA of an nucleic acid encoding a polypeptide having an amino acid sequence of SEQ ID NO;

2 in a biological sample from the subject; and

an instructional material for use of the primers or the probe to determine the presence or the absence of the cDNA in the biological sample.

8. The kit of claim 7, wherein the nucleic acid has a sequence of SEQ ID NO:

1.

9. The kit of claim 7, wherein the tumor is selected from the group consisting of lung cancer, hepatocellular cancer, colon cancer, cervical cancer and estrogen receptor alpha negative breast cancer.

10. The kit of claim 8, wherein the tumor is selected from the group consisting of lung cancer, hepatocellular cancer, colon cancer, cervical cancer and estrogen receptor alpha negative breast cancer.

11. The kit of claim 7, wherein the biological sample is selected from the group consisting of a serum, a plasma, and a tissue.

12-15. -15. (canceled)

16. A method for diagnosing a subject suffering from or suspected of suffering from a tumor, or for evaluating the treatment outcome of an anticancer agent in a subject suffering from a tumor, with the proviso that the tumor is not an estrogen receptor alpha positive breast cancer, comprising:

providing a biological sample from the subject; and

detecting the cDNA of a nucleic acid encoding a polypeptide having an amino acid sequence of SEQ ID NO;

2 in the sample,

wherein the presence of the cDNA in the sample indicates the subject is suffering from a tumor or has a drug resistance against the anticancer agent.

17. The method of claim 16, wherein the nucleic acid has a sequence of SEQ ID NO:

1

18. The method of claim 16, wherein the tumor is selected from the group consisting of lung cancer, hepatocellular cancer, colon cancer, cervical cancer and estrogen receptor alpha negative breast cancer.

19. The method of claim 17, wherein the tumor is selected from the group consisting of lung cancer, hepatocellular cancer, colon cancer, cervical cancer and estrogen receptor alpha negative breast cancer.

20. The method of claim 16, wherein the biological sample is selected from the group consisting of a serum, a plasma, and a tissue.

21-30. -30. (canceled)